Effect of prostaglandin-mediated platelet-suppressant drugs on acute cardiovascular catastrophes.
D001241:Aspirin / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects; D002561:Cerebrovascular Disorders / Q000188:drug therapy; D002986:Clinical Trials as Topic; D001026:Coronary Artery Bypass; D003327:Coronary Disease / Q000401:mortality / Q000517:prevention & control*; D004176:Dipyridamole / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D009203:Myocardial Infarction / Q000150:complications / Q000401:mortality; D011183:Postoperative Complications / Q000517:prevention & control; D013442:Sulfinpyrazone / Q000627:therapeutic use*; D013923:Thromboembolism / Q000517:prevention & control
D004176:Dipyridamole; D001241:Aspirin; D013442:Sulfinpyrazone